Levetiracetam (Epilepsy) updated on 04-22-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16084
R66745		 Christensen (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.09 [0.80;1.49] C
excluded (control group) 		50/1,063   230/5,299 280 1,063
ref
S16038
R66570		 Christensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.08 [0.79;1.47] 50/1,063   1,006/22,227 1,056 1,063
ref
S10072
R36662		 Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 1.65 [1.20;2.28] C
excluded (control group) 		60/621   128/2,108 188 621
ref
S7807
R23110		 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.89 [1.45;2.47] C 60/621   91,455/1,710,441 91,515 621
ref
Total 2 studies 1.44 [0.83;2.49] 92,571 1,684
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024Christensen, 2024 1 1.08[0.79; 1.47]1,0561,06349%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Levetiracetam) (Controls unexposed, NOS), 2020Coste, 2020 2 1.89[1.45; 2.47]91,51562151%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 86% 1.44[0.83; 2.49]92,5711,6840.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Epilepsy) (Controls unexposed, general population; 2: Levetiracetam) (Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.44[0.83; 2.49]92,5711,68486%NAChristensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.89[1.45; 2.47]91,515621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 1.08[0.79; 1.47]1,0561,063 -NAChristensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024 1 Tags Adjustment   - No  - No 1.89[1.45; 2.47]91,515621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1   - Yes  - Yes 1.08[0.79; 1.47]1,0561,063 -NAChristensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024 1 All studiesAll studies 1.44[0.83; 2.49]92,5711,68486%NAChristensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10072, 16084

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.89[1.45; 2.47]91,515621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1 unexposed, sick controlsunexposed, sick controls 1.08[0.79; 1.47]1,0561,063 -NAChristensen (Levetiracetam) (Epilepsy) (Controls unexposed, general population), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.34[0.89; 2.02]4681,68470%NAChristensen (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2024 Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 20.510.01.0